# NRG Oncology

Source: https://onco.cc/companies/nrg-oncology/  
OnCo record `nrg-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The US cooperative group formed from the radiation, gynaecologic, and breast trial groups; it co-led OlympiA, the trial that put a PARP inhibitor after surgery for BRCA carriers.

## Summary

NRG Oncology, based in Philadelphia, is the US cooperative group formed in 2014 by the merger of NSABP, RTOG and GOG, and it runs radiation, breast, gynaecologic and central nervous system trials within the NCI National Clinical Trials Network. It co-led OlympiA with the Breast International Group and AstraZeneca, the trial that put adjuvant olaparib after surgery for BRCA carriers, and the RTOG prostate radiation trials whose slides trained ArteraAI Prostate; NRG-GY018, the HPV-positive de-escalation studies NRG-HN002 and NRG-HN005 and OUTBACK are also in OnCo, with Bernard Fisher, Charles E. Geyer Jr. and Lori J. Pierce among the people linked. OnCo connects it to bottlenecks on slow enrolment and on surgery and radiotherapy getting the least trial money. Whether a standing platform for drugs with radiotherapy can be funded is the open idea. Its programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: NRG; Radiation Therapy Oncology Group; RTOG
- Tags: cooperative-group
- HQ: Philadelphia, PA
- Type: cooperative-group
- Website: https://www.nrgoncology.org

## Notes

- NCTN cooperative group
- OlympiA (with BIG)
- RTOG prostate radiation trials
- Gynaecologic oncology (former GOG)

## Sources

- Official website: https://www.nrgoncology.org

## Connected records

- drugs: [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/), [Olaparib](https://onco.cc/drugs/olaparib/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- institutions: [American Society for Radiation Oncology](https://onco.cc/institutions/astro/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Orlando Health Cancer Institute](https://onco.cc/institutions/orlando-health-cancer-institute/), [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/), [Stephenson Cancer Center, OU Health](https://onco.cc/institutions/stephenson-oklahoma/), [UPMC Hillman Cancer Center](https://onco.cc/institutions/upmc-hillman/), [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/)
- trials: [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [CIRCULATE-US](https://onco.cc/trials/circulate-us/), [Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery](https://onco.cc/trials/nct04068103/), [Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer](https://onco.cc/trials/nct01993810/), [Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer](https://onco.cc/trials/nct04333537/), [Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer](https://onco.cc/trials/nct02488967/), [Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00004054/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [NRG CC001](https://onco.cc/trials/nrg-cc001/), [NRG Oncology RTOG 0521](https://onco.cc/trials/rtog-0521/), [NRG-GY018 / KEYNOTE-868](https://onco.cc/trials/nrg-gy018-keynote-868/), [NRG-HN002 & NRG-HN005 (HPV+ de-escalation)](https://onco.cc/trials/nrg-hn002-hn005/), [NSABP B-04](https://onco.cc/trials/nsabp-b04/), [NSABP B-06](https://onco.cc/trials/nsabp-b06/), [NSABP B-32](https://onco.cc/trials/nsabp-b32/), [NSABP B-39/RTOG 0413](https://onco.cc/trials/nsabp-b39/), [NSABP B-51 / RTOG 1304](https://onco.cc/trials/nsabp-b51/), [OlympiA](https://onco.cc/trials/olympia/), [OUTBACK / ANZGOG 0902 / GOG-0274](https://onco.cc/trials/outback/), [Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer](https://onco.cc/trials/nct00003139/), [Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer](https://onco.cc/trials/nct00567580/), [Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00936390/), [RTOG 0129 (HPV analysis)](https://onco.cc/trials/rtog-0129/), [RTOG 0415](https://onco.cc/trials/rtog-0415/), [RTOG 0617](https://onco.cc/trials/rtog-0617/), [RTOG 1016](https://onco.cc/trials/rtog-1016/), [RTOG 91-11](https://onco.cc/trials/rtog-91-11/), [RTOG 92-02](https://onco.cc/trials/rtog-9202/), [RTOG 94-08](https://onco.cc/trials/rtog-9408/), [RTOG 9402](https://onco.cc/trials/rtog-9402/), [RTOG 9601](https://onco.cc/trials/rtog-9601/), [Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer](https://onco.cc/trials/nct00551525/), [Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct06958328/), [Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial](https://onco.cc/trials/nct04513717/)
- people: [Bernard Fisher](https://onco.cc/people/bernard-fisher/), [Charles E. Geyer Jr.](https://onco.cc/people/charles-geyer/), [Deborah Watkins Bruner](https://onco.cc/people/deborah-bruner/), [Lori J. Pierce](https://onco.cc/people/lori-pierce/)
- bottlenecks: [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- ideas: [A standing platform for testing new drugs with radiotherapy](https://onco.cc/ideas/idea-tr2-rt-drug-platform/), [A statutory minimum share of public trial money for surgery and radiotherapy](https://onco.cc/ideas/idea-fund-non-drug-trial-quota/), [Core-funded radiotherapy trials infrastructure with central quality assurance](https://onco.cc/ideas/idea-fund-radiotherapy-trials-infrastructure/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/), [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- companies: [Breast International Group (BIG)](https://onco.cc/companies/big/), [GOG Foundation](https://onco.cc/companies/gog-foundation/), [NSABP Foundation](https://onco.cc/companies/nsabp-foundation/)

---
JSON: https://onco.cc/api/v1/entities/nrg-oncology.json